Tulathromycin A是一种大环内酯类抗生素，靶向细菌核糖体抑制蛋白质合成 (IC50=0.26 μM)，具有免疫调节作用。它可研究牛和猪的呼吸道疾病。

Tulathromycin A is a macrolide antibiotic.

145 calves were inoculated by two highly pathogenic strains of M. bovis (with minimum inhibitory concentration values for tulathromycin of 1 and >64 μg/ml). Four days after inoculation, calves with clinical BRD were treated subcutaneously with saline or tulathromycin (2.5 mg/kg). Compared with saline, BRD-related withdrawals, peak rectal temperatures, and lung lesion scores were significantly lower for tulathromycin-treated calves (P< .01). Tulathromycin was highly effective in the treatment of BRD due to M. bovis in calves regardless of the minimum inhibitory concentration of the challenge strain (1 or >64 μg/ml). The MIC90 for tulathromycin were 1 μg/ml for Pasteurella multocida (bovine), 2 μg/ml for Mannheimia (Pasteurella) haemolytica, and 2 μg/ml for Pasteurella multocida (porcine) and ranged from 4-16 μg/ml for Actinobacillus pleuropneumoniae and from 0.5-4 μg/ml for Histophilus somni (Haemophilus somnus).

Each study randomly allocated 250 calves to receive tulathromycin at 2.5 mg/kg and 250 calves to receive either florfenicol at 40 mg/kg or tilmicosin at 10 mg/kg on arrival at the feedlot. Calves were housed by treatment group in pens with 50 calves/pen. The treatment groups were physiologic saline (n=160) given SC at 0.02 ml/kg, tulathromycin (n=20) given SC at 2.5 mg/kg, and tilmicosin (n = 320) given SC at 10 mg/kg.

217500-96-4

C41H79N3O12

806.09

Tulathromycin;托拉菌素 A;CP 472295;Draxxin

DMSO:45 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years